Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Proof-of-Concept Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Hemophilic Arthropathy

NCT02994147 is registered in ClinicalTrials.gov with TWi Biotechnology, Inc. as lead sponsor.

NCT NCT02994147
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02994147 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Proof-of-Concept Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Hemophilic Arthropathy
Lead sponsor
TWi Biotechnology, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 21, 2017
Completion date
October 2, 2019
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilic arthropathy